News

  • Transition of CEO role

    Posted on 15 May 2013

    The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited. 

  • Photonz's Chief Scientific Officer Wins NZBIO Award

    Posted on 20 March 2013

    Dr Hywel Griffiths, Chief Scientific Officer for Photonz Corp. was named the 2013 Young Biotechnologist of the Year by NZBIO at an award ceremony Tuesday evening.

     

  • Seeking commercial partners

    Posted on 9 November 2012

    AUCKLAND via ALGAE WORLD ASIA CONFERENCE SINGAPORE – 8 November 2012 – Talks are underway involving potential partners of Photonz Corporation as the company is finalising its process for manufacturing eicosapentaenoic acid (EPA) by fermentation of micro-algae.

 

Photonz receives $2.9 million R+D Grant

Posted on Mar. 28, 2011

Awarded under the TechNZ programme, the grant will enable the biotech company to undertake work that will, when completed, allow it to commence commercial production of the omega-3 fatty acid eicosapentaenoic acid (EPA) from marine micro-algae.

Currently EPA for pharmaceuticals can only be sourced from fish oil. Photonz has developed a unique process to produce high-quality, high-value EPA from marine microalgae as a critical ingredient in novel therapeutics for the US$60 billion cardiovascular disease market. Photonz's EPA, which is sustainably produced, will mean that pharmaceutical manufacturers will not have to rely on limited stocks of natural fisheries as their only source of EPA.

The company currently operates a prototype industrial fermentation plant and in April 2010 harvested the first batch of algal biomass. The grant will enable Photonz to complete its process development programme, proving the full manufacturing process at prototype industrial scale. It will also fund the development of a technology transfer package that will enable the process to be implemented at full industrial scale by a contract manufacturer. The company is currently in discussions with potential manufacturing partners.

"This injection of capital will enable Photonz to maintain its pace of development, accelerating our commercialisation plans," said Chief Executive, Greg Moss-Smith. "It's a vote of confidence in our strategy and our ability to execute."

This is the third grant Photonz has received from FRST. Since its formation in April 2002 Photonz has issued 9,594,885 shares and has raised in excess of $6.2 million in capital to fund the company's progress.

ENDS


Founded in New Zealand in 2002, Photonz Corporation produces the high-quality, high-value omega-3 fatty acid, eicosapentaenoic acid (EPA), a critical ingredient in novel therapeutics for the cardiovascular disease market. Photonz has developed a unique fermentation process which allows it to produce EPA directly from marine microalgae, making it a reliable and sustainable ingredient for the pharmaceutical industry. Photonz currently has a pilot industrial scale plant producing samples and aims to begin manufacturing at industrial scale in 2012. For more information please visit www.photonzcorp.com

For media inquiries please contact:
Allan Botica, Botica Butler Raudon, +64 21 400 500 or allanb@botica.co.nz
Richard Justice, Photonz, +64 21 223 4741 or rjustice@photonzcorp.com